Clinical Trial Update: Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates trebananib in younger patients with relapsed or refractory solid tumors, including central nervous system tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasm
• Solid Tumor

Drugs mentioned

• Trebananib (trebananib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Central Nervous System Neoplasm, Solid Neoplasm | Phase 1 | Status: COMPLETED